Account wins from the 02/03 News Brief

Share this article:
PDI has entered a three-year agreement with Align Pharmaceuticals to assist the latter with the commercialization of its new product entries for the oncology market. PDI will initially provide a sales team of 40 field reps to oversee the sales of three oncology products recently acquired by Align. Two of the drugs, Numoisyn Lozenges and Numoisyn Liquid, were designed for xerostomia or dry mouth caused by radiation therapy, or Sjogren’s syndrome. Xclair, the third product, was approved to treat the symptoms of radiation dermatitis. The primary audience will be radiation oncologists, with additional calls made to select rheumatologists.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters